[
Awah CU, Winter J, Ogunwobi OO. Genome scale CRISPR Cas9a knockout screen reveals genes that control glioblastoma susceptibility to the alkylating agent temozolomide. All Life. 2022;15(1):88-93. doi: 10.1080/26895293.2021.2024895. Epub 2022 Jan 10. PMID: 35990011; PMCID: PMC9389140.

Links: 
Zenodo links:[
https://zenodo.org/record/5167143/files/5953_DMSO_Day14_R2.txt?download=1
https://zenodo.org/record/5167143/files/6377_Library.txt?download=1
https://zenodo.org/record/5167143/files/6396_Puromycin_Day0.txt?download=1
https://zenodo.org/record/5167143/files/6397_Puromycin_Day14.txt?download=
https://zenodo.org/record/5167143/files/6398_DMSO_Day14.txt?download=1
https://zenodo.org/record/5167143/files/6399_Temozolomide_Day14.txt?download=1
]
]

[
Biayna J, Garcia-Cao I, Álvarez MM, Salvadores M, Espinosa-Carrasco J, McCullough M, Supek F, Stracker TH. Loss of the abasic site sensor HMCES is synthetic lethal with the activity of the APOBEC3A cytosine deaminase in cancer cells. PLoS Biol. 2021 Mar 31;19(3):e3001176. doi: 10.1371/journal.pbio.3001176. PMID: 33788831; PMCID: PMC8041192.

Links:
Gene-level data for all primary screens: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041192/bin/pbio.3001176.s014.xlsx
]

[
Xu S, Zhan M, Jiang C, He M, Yang L, Shen H, Huang S, Huang X, Lin R, Shi Y, Liu Q, Chen W, Mohan M, Wang J. Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer. Nat Commun. 2019 Dec 2;10(1):5492. doi: 10.1038/s41467-019-13420-x. PMID: 31792210; PMCID: PMC6889377.

Links:
Supplementary Data 1: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889377/bin/41467_2019_13420_MOESM4_ESM.xlsx
]

[
Yang H, Liu B, Liu D, Yang Z, Zhang S, Xu P, Xing Y, Kutschick I, Pfeffer S, Britzen-Laurent N, Grützmann R, Pilarsky C. Genome-Wide CRISPR Screening Identifies DCK and CCNL1 as Genes That Contribute to Gemcitabine Resistance in Pancreatic Cancer. Cancers (Basel). 2022 Jun 27;14(13):3152. doi: 10.3390/cancers14133152. PMID: 35804923; PMCID: PMC9264918.

Links:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264918/bin/cancers-14-03152-s001.zip
]

[
Oshima K, Zhao J, Pérez-Durán P, Brown JA, Patiño-Galindo JA, Chu T, Quinn A, Gunning T, Belver L, Ambesi-Impiombato A, Tosello V, Wang Z, Sulis ML, Kato M, Koh K, Paganin M, Basso G, Balbin M, Nicolas C, Gastier-Foster JM, Devidas M, Loh ML, Paietta E, Tallman MS, Rowe JM, Litzow M, Minden MD, Meijerink J, Rabadan R, Ferrando A. Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. Nat Cancer. 2020 Nov;1(11):1113-1127. doi: 10.1038/s43018-020-00124-1. Epub 2020 Oct 19. PMID: 33796864; PMCID: PMC8011577.

Links:
Supplementary Table 7: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011577/bin/NIHMS1673078-supplement-Supplementary_Table_7.xlsx
]

[
Ramaker RC, Hardigan AA, Gordon ER, Wright CA, Myers RM, Cooper SJ. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition. BMC Cancer. 2021 May 29;21(1):632. doi: 10.1186/s12885-021-08388-1. PMID: 34049503; PMCID: PMC8164247.

Links:
Table S5: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164247/bin/12885_2021_8388_MOESM1_ESM.xlsx
]

[
Song WM, Chia PL, Zhou X, Walsh M, Silva J, Zhang B. Pseudo-temporal dynamics of chemoresistant triple negative breast cancer cells reveal EGFR/HER2 inhibition as synthetic lethal during mid-neoadjuvant chemotherapy. iScience. 2023 Jan 27;26(2):106064. doi: 10.1016/j.isci.2023.106064. PMID: 36824282; PMCID: PMC9942122.

Links:
Table S1. CRISPR-Cas9 screening results for paclitaxel (A) and doxorubicin (B) resistance in MCF10A cells Chemo-promoting/-sensitizing knock-outs (z-score >1.96 or z-score <−1.96) are highlighted by red/blue in column, z.3VS5.Paclitaxel_VS_T0: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942122/bin/mmc2.xlsx
]

[
Lan B, Zeng S, Zhang S, Ren X, Xing Y, Kutschick I, Pfeffer S, Frey B, Britzen-Laurent N, Grützmann R, Cordes N, Pilarsky C. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Cancers (Basel). 2022 Jan 10;14(2):326. doi: 10.3390/cancers14020326. PMID: 35053488; PMCID: PMC8773906.

Links:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773906/bin/cancers-14-00326-s001.zip
]

[
Huang K, Liu X, Li Y, Wang Q, Zhou J, Wang Y, Dong F, Yang C, Sun Z, Fang C, Liu C, Tan Y, Wu X, Jiang T, Kang C. Genome-Wide CRISPR-Cas9 Screening Identifies NF-κB/E2F6 Responsible for EGFRvIII-Associated Temozolomide Resistance in Glioblastoma. Adv Sci (Weinh). 2019 Jul 24;6(17):1900782. doi: 10.1002/advs.201900782. PMID: 31508283; PMCID: PMC6724471.

Links:
Table S5: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724471/bin/ADVS-6-1900782-s005.xlsx
Table S6: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724471/bin/ADVS-6-1900782-s006.xlsx
]

[
Liu Y, Azizian NG, Sullivan DK, Li Y. mTOR inhibition attenuates chemosensitivity through the induction of chemotherapy resistant persisters. Nat Commun. 2022 Nov 17;13(1):7047. doi: 10.1038/s41467-022-34890-6. PMID: 36396656; PMCID: PMC9671908.

Links:
Supplementary Data 1: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671908/bin/41467_2022_34890_MOESM5_ESM.xlsx
]

[
Zelceski A, Francica P, Lingg L, Mutlu M, Stok C, Liptay M, Alexander J, Baxter JS, Brough R, Gulati A, Haider S, Raghunandan M, Song F, Sridhar S, Forment JV, O'Connor MJ, Davies BR, van Vugt MATM, Krastev DB, Pettitt SJ, Tutt ANJ, Rottenberg S, Lord CJ. MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells. Cell Rep. 2023 May 30;42(5):112484. doi: 10.1016/j.celrep.2023.112484. Epub 2023 May 9. PMID: 37163373.

Links:
Table S1. Supplemental data including: CRISPRn and CRISPRi screen data, shRNA screen data, KEGG analysis of CRISPR screen data, mRNA and protein expression data for MND1, PSMC3IP, BRCA1, BRCA2, and primer guide RNA sequences: https://https://ars.els-cdn.com/content/image/1-s2.0-S2211124723004953-mmc2.xlsx
]

[
Wang Y, Wu J, Chen H, Yang Y, Xiao C, Yi X, Shi C, Zhong K, He H, Li Y, Wu Z, Zhou G, Rao Q, Wang X, Zhou X, Lomberk G, Liu B, Zhao J, Ge J, Zhou W, Chu X, Chen C, Zhou X, Wang L, Guan K, Qu L. Genome-wide CRISPR-Cas9 screen identified KLF11 as a druggable suppressor for sarcoma cancer stem cells. Sci Adv. 2021 Jan 27;7(5):eabe3445. doi: 10.1126/sciadv.abe3445. PMID: 33571129; PMCID: PMC7840125.

Links:
Table S1: https://www.science.org/doi/suppl/10.1126/sciadv.abe3445/suppl_file/abe3445_table_s1.xlsx
]

[
He YJ, Meghani K, Caron MC, Yang C, Ronato DA, Bian J, Sharma A, Moore J, Niraj J, Detappe A, Doench JG, Legube G, Root DE, D'Andrea AD, Drané P, De S, Konstantinopoulos PA, Masson JY, Chowdhury D. DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells. Nature. 2018 Nov;563(7732):522-526. doi: 10.1038/s41586-018-0670-5. Epub 2018 Oct 31. PMID: 30464262; PMCID: PMC7155769.

Links:
Table 1: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155769/bin/NIHMS1567675-supplement-Table_1.xlsx
]

[
Goodspeed A, Jean A, Costello JC. A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer. Eur Urol. 2019 Feb;75(2):242-250. doi: 10.1016/j.eururo.2018.10.040. Epub 2018 Nov 7. PMID: 30414698; PMCID: PMC6339584.

Links:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339584/bin/NIHMS1510205-supplement-1.xlsx
]

[
Deng L, Yang L, Zhu S, Li M, Wang Y, Cao X, Wang Q, Guo L. Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screening. Cell Death Discov. 2023 Feb 2;9(1):40. doi: 10.1038/s41420-023-01315-2. PMID: 36725843; PMCID: PMC9892530.

Links:
Table S1 The sgRNA enrichmen between DMSO and chemo-treatment in H69-AR: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892530/bin/41420_2023_1315_MOESM8_ESM.xlsx
]

[
Tian X, Wang X, Cui Z, Liu J, Huang X, Shi C, Zhang M, Liu T, Du X, Li R, Huang L, Gong D, Tian R, Cao C, Jin P, Zeng Z, Pan G, Xia M, Zhang H, Luo B, Xie Y, Li X, Li T, Wu J, Zhang Q, Chen G, Hu Z. A Fifteen-Gene Classifier to Predict Neoadjuvant Chemotherapy Responses in Patients with Stage IB to IIB Squamous Cervical Cancer. Adv Sci (Weinh). 2021 Mar 18;8(10):2001978. doi: 10.1002/advs.202001978. PMID: 34026427; PMCID: PMC8132153.

Links:
Supporting Table 9: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132153/bin/ADVS-8-2001978-s005.xlsx
]

[
Balmus G, Pilger D, Coates J, Demir M, Sczaniecka-Clift M, Barros AC, Woods M, Fu B, Yang F, Chen E, Ostermaier M, Stankovic T, Ponstingl H, Herzog M, Yusa K, Martinez FM, Durant ST, Galanty Y, Beli P, Adams DJ, Bradley A, Metzakopian E, Forment JV, Jackson SP. ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks. Nat Commun. 2019 Jan 8;10(1):87. doi: 10.1038/s41467-018-07729-2. PMID: 30622252; PMCID: PMC6325118.

Links:
Supplementary Data 1: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325118/bin/41467_2018_7729_MOESM3_ESM.xlsx
Supplementary Data 2: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325118/bin/41467_2018_7729_MOESM4_ESM.xlsx
]

[
Rocha CRR, Reily Rocha A, Molina Silva M, Rodrigues Gomes L, Teatin Latancia M, Andrade Tomaz M, de Souza I, Karolynne Seregni Monteiro L, Menck CFM. Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries. Cells. 2020 Dec 1;9(12):2573. doi: 10.3390/cells9122573. PMID: 33271924; PMCID: PMC7760831.

Links:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760831/bin/cells-09-02573-s001.xlsx
]

[
Xie C, Li K, Li Y, Peng X, Teng B, He K, Jin A, Wang W, Wei Z. CRISPR-based knockout screening identifies the loss of MIEF2 to enhance oxaliplatin resistance in colorectal cancer through inhibiting the mitochondrial apoptosis pathway. Front Oncol. 2022 Aug 29;12:881487. doi: 10.3389/fonc.2022.881487. PMID: 36106106; PMCID: PMC9465453.

Links:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465453/bin/DataSheet_1.zip
]

[
Wei X, Yang J, Adair SJ, Ozturk H, Kuscu C, Lee KY, Kane WJ, O'Hara PE, Liu D, Demirlenk YM, Habieb AH, Yilmaz E, Dutta A, Bauer TW, Adli M. Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells. Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28068-28079. doi: 10.1073/pnas.2009899117. Epub 2020 Oct 23. PMID: 33097661; PMCID: PMC7668168.

Links:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668168/bin/pnas.2009899117.sd01.csv
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668168/bin/pnas.2009899117.sd02.csv
]

[
Zhu GD, Yu J, Sun ZY, Chen Y, Zheng HM, Lin ML, Ou-Yang S, Liu GL, Zhang JW, Shao FM. Genome-wide CRISPR/Cas9 screening identifies CARHSP1 responsible for radiation resistance in glioblastoma. Cell Death Dis. 2021 Jul 21;12(8):724. doi: 10.1038/s41419-021-04000-3. PMID: 34290231; PMCID: PMC8295287.

Links:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295287/bin/41419_2021_4000_MOESM4_ESM.xlsx
]

[
Funke K, Einsfelder U, Hansen A, Arévalo L, Schneider S, Nettersheim D, Stein V, Schorle H. Genome-scale CRISPR screen reveals neddylation to contribute to cisplatin resistance of testicular germ cell tumours. Br J Cancer. 2023 Jun;128(12):2270-2282. doi: 10.1038/s41416-023-02247-5. Epub 2023 Apr 6. PMID: 37024667; PMCID: PMC10241889.

Links:
Supplementary Data Set S1: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241889/bin/41416_2023_2247_MOESM3_ESM.xlsx
]

[
Nguyen NHK, Rafiee R, Tagmount A, Sobh A, Loguinov A, de Jesus Sosa AK, Elsayed AH, Gbadamosi M, Seligson N, Cogle CR, Rubnitz J, Ribeiro R, Downing J, Cao X, Pounds SB, Vulpe CD, Lamba JK. Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML. Blood Adv. 2023 May 9;7(9):1769-1783. doi: 10.1182/bloodadvances.2022007934. PMID: 36111891; PMCID: PMC10182178.

Links:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182178/bin/BLOODA_ADV-2022-007934-mmc1.xlsx
]

[
Sanchez-Burgos L, Navarro-González B, García-Martín S, Sirozh O, Mota-Pino J, Fueyo-Marcos E, Tejero H, Antón ME, Murga M, Al-Shahrour F, Fernandez-Capetillo O. Activation of the integrated stress response is a vulnerability for multidrug-resistant FBXW7-deficient cells. EMBO Mol Med. 2022 Sep 7;14(9):e15855. doi: 10.15252/emmm.202215855. Epub 2022 Jul 21. PMID: 35861150; PMCID: PMC9449593.

Links:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449593/bin/EMMM-14-e15855-s001.xlsx
]

[
Chen JZ, Wang LN, Luo XQ, Tang YL. The genomic landscape of sensitivity to arsenic trioxide uncovered by genome-wide CRISPR-Cas9 screening. Front Oncol. 2023 May 12;13:1178686. doi: 10.3389/fonc.2023.1178686. PMID: 37251921; PMCID: PMC10214836.

Links:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214836/bin/Table_1.xlsx
]

[
Cai MY, Dunn CE, Chen W, Kochupurakkal BS, Nguyen H, Moreau LA, Shapiro GI, Parmar K, Kozono D, D'Andrea AD. Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in Double-Strand Break End Resection. Cell Rep. 2020 Feb 18;30(7):2402-2415.e5. doi: 10.1016/j.celrep.2020.01.052. PMID: 32075772; PMCID: PMC8713357.

Links:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713357/bin/NIHMS1563617-supplement-2.xlsx
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713357/bin/NIHMS1563617-supplement-3.xlsx
]

[
Liu C, Banister CE, Buckhaults PJ. Spindle Assembly Checkpoint Inhibition Can Resensitize p53-Null Stem Cells to Cancer Chemotherapy. Cancer Res. 2019 May 1;79(9):2392-2403. doi: 10.1158/0008-5472.CAN-18-3024. Epub 2019 Mar 12. PMID: 30862715; PMCID: PMC6497569.

Links:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497569/bin/NIHMS1524158-supplement-5.xlsx
]

[
Awah CU, Chen L, Bansal M, Mahajan A, Winter J, Lad M, Warnke L, Gonzalez-Buendia E, Park C, Zhang D, Feldstein E, Yu D, Zannikou M, Balyasnikova IV, Martuscello R, Konerman S, Győrffy B, Burdett KB, Scholtens DM, Stupp R, Ahmed A, Hsu P, Sonabend AM. Ribosomal protein S11 influences glioma response to TOP2 poisons. Oncogene. 2020 Jul;39(27):5068-5081. doi: 10.1038/s41388-020-1342-0. Epub 2020 Jun 11. PMID: 32528131; PMCID: PMC7646677.

Links:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646677/bin/NIHMS1599130-supplement-1599130_SuppList_Data_1B.xlsx
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646677/bin/NIHMS1599130-supplement-1599130_SuppList_Data_6.xlsx
]

[
Gallo D, Young JTF, Fourtounis J, Martino G, Álvarez-Quilón A, Bernier C, Duffy NM, Papp R, Roulston A, Stocco R, Szychowski J, Veloso A, Alam H, Baruah PS, Fortin AB, Bowlan J, Chaudhary N, Desjardins J, Dietrich E, Fournier S, Fugère-Desjardins C, Goullet de Rugy T, Leclaire ME, Liu B, Bhaskaran V, Mamane Y, Melo H, Nicolas O, Singhania A, Szilard RK, Tkáč J, Yin SY, Morris SJ, Zinda M, Marshall CG, Durocher D. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Nature. 2022 Apr;604(7907):749-756. doi: 10.1038/s41586-022-04638-9. Epub 2022 Apr 20. PMID: 35444283; PMCID: PMC9046089.

Links:
Supplementary Table 1: Read counts for CRISPR screens conducted in this study. Tab 1 contains read counts for CCNE1 synthetic lethal screens in parental and CCNE1 (C2 and C21) RPE1-hTERT TP53−/− using the TKOv2 library. Tab2 contains read counts for CCNE1 synthetic lethal screens in parental and CCNE1 (C2) RPE1-hTERT TP53−/− using the TKOv3 library. Tab 3 contains read counts for RP-6306 resistance screen in parental and CCNE1 (C3 and C4) FT282-hTERT TP53R175H using the TKOv3 library: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046089/bin/41586_2022_4638_MOESM3_ESM.xlsx
]

[
Masoudi M, Seki M, Yazdanparast R, Yachie N, Aburatani H. A genome-scale CRISPR/Cas9 knockout screening reveals SH3D21 as a sensitizer for gemcitabine. Sci Rep. 2019 Dec 16;9(1):19188. doi: 10.1038/s41598-019-55893-2. PMID: 31844142; PMCID: PMC6915784.

Links:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915784/bin/41598_2019_55893_MOESM2_ESM.xlsx
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915784/bin/41598_2019_55893_MOESM3_ESM.xlsx
]

